JP2024508749A - クローンｔ細胞増殖を処置するための方法および材料 - Google Patents

クローンｔ細胞増殖を処置するための方法および材料 Download PDF

Info

Publication number
JP2024508749A
JP2024508749A JP2023549562A JP2023549562A JP2024508749A JP 2024508749 A JP2024508749 A JP 2024508749A JP 2023549562 A JP2023549562 A JP 2023549562A JP 2023549562 A JP2023549562 A JP 2023549562A JP 2024508749 A JP2024508749 A JP 2024508749A
Authority
JP
Japan
Prior art keywords
polypeptide
binding
antigen
binding domain
trbc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508749A5 (https=
Inventor
マイケル エス． ワン
ケネス ダブリュ． キンズラー
ブライアン ジェイ． モグ
ニコラス パパドポウロス
アンドリュー パードール
スマン ポール
バート フォーゲルシュタイン
シビン チョウ
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2024508749A publication Critical patent/JP2024508749A/ja
Publication of JP2024508749A5 publication Critical patent/JP2024508749A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023549562A 2021-02-17 2022-02-15 クローンｔ細胞増殖を処置するための方法および材料 Pending JP2024508749A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150232P 2021-02-17 2021-02-17
US63/150,232 2021-02-17
PCT/US2022/016423 WO2022177889A1 (en) 2021-02-17 2022-02-15 Methods and materials for treating clonal t cell expansions

Publications (2)

Publication Number Publication Date
JP2024508749A true JP2024508749A (ja) 2024-02-28
JP2024508749A5 JP2024508749A5 (https=) 2025-02-17

Family

ID=80595091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549562A Pending JP2024508749A (ja) 2021-02-17 2022-02-15 クローンｔ細胞増殖を処置するための方法および材料

Country Status (7)

Country Link
US (1) US20240124608A1 (https=)
EP (1) EP4294841A1 (https=)
JP (1) JP2024508749A (https=)
CN (1) CN117561277A (https=)
AU (1) AU2022222679A1 (https=)
CA (1) CA3211203A1 (https=)
WO (1) WO2022177889A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025220689A1 (ja) * 2024-04-17 2025-10-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｔ細胞機能不全のｔ細胞性腫瘍患者に有効な二重特異性抗体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
WO2025007013A2 (en) * 2023-06-28 2025-01-02 The Johns Hopkins University Trbc targeting antibody-drug conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020527027A (ja) * 2017-06-09 2020-09-03 オートラス リミテッド 抗ｔｒｂｃ１抗原結合ドメイン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3241561T3 (da) 2014-03-05 2025-06-30 Autolus Ltd Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2
GB201817172D0 (en) * 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) * 2018-10-31 2018-12-19 Autolus Ltd Binding domain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020527027A (ja) * 2017-06-09 2020-09-03 オートラス リミテッド 抗ｔｒｂｃ１抗原結合ドメイン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 19, no. 8, JPN6026003724, 2006, pages 359 - 367, ISSN: 0005785640 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025220689A1 (ja) * 2024-04-17 2025-10-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｔ細胞機能不全のｔ細胞性腫瘍患者に有効な二重特異性抗体

Also Published As

Publication number Publication date
EP4294841A1 (en) 2023-12-27
CA3211203A1 (en) 2022-08-25
WO2022177889A1 (en) 2022-08-25
AU2022222679A1 (en) 2023-09-07
US20240124608A1 (en) 2024-04-18
CN117561277A (zh) 2024-02-13

Similar Documents

Publication Publication Date Title
JP7084990B2 (ja) 三重特異性タンパク質と使用方法
US20240218077A1 (en) Anti-cd47 agent-based treatment of cd20-positive cancer
AU2018250336B2 (en) Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
JP2024508749A (ja) クローンｔ細胞増殖を処置するための方法および材料
CN107847587A (zh) Cd30×cd16抗体与pd‑1拮抗剂的联合药物用于治疗
CN115920007A (zh) 组合
JP2022532490A (ja) 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ
CN105579058A (zh) Cd38激动剂的医学用途
CN112292140B (zh) 靶向cd37和cd19的嵌合抗原受体
EP3691661A1 (en) Combination for t-cell immunotherapy and use thereof
JP2021501217A (ja) 同種キメラ抗原受容体ｔ細胞投与のための方法および組成物
JP2023551535A (ja) Ｔ細胞がんを治療するための方法および材料
JP2024513506A (ja) がんの治療のためのＣＤ４７／ＳＩＲＰα結合及びＮＥＤＤ８活性化酵素Ｅ１調節サブユニットの共阻害
KR20200068746A (ko) Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells)
KR20210143896A (ko) 암 요법에 사용하기 위한 세마포린-4d 길항제
US20230134725A1 (en) Fusion Protein Extensions
KR20250029015A (ko) 다발성 골수종의 치료를 위한, 다른 제제와 조합된 이사툭시맙의 용도
US20230241237A1 (en) Immune Cell Redirecting Compositions and Therapeutic Uses Thereof
AU2007209787B2 (en) Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
WO2026060097A1 (en) Methods and materials for targeting c-c chemokine receptor-like 2 (ccrl2)
CN118201614A (zh) 用于癌症治疗的tlr7激动剂及组合
HK40119904A (zh) 含有抗人表皮生长因子受体2(her2)嵌合抗原受体(car)的自然杀伤细胞的给药方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260202